1
|
Falkensammer B, Fasser W, Scherer K, Zemann A, Parson W, Ulmer H, Dierich MP, Stoiber H. Drug Monitoring and Viral Response to Lopinavir/Ritonavir or Saquinavir/Ritonavir Containing Regimens in Individuals Infected with the Human Immunodeficiency Virus Type1. Int J Immunopathol Pharmacol 2016; 18:145-54. [PMID: 15698519 DOI: 10.1177/039463200501800115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aim of this study was to correlate results of therapeutic drug monitoring, genotypic resistance and viral response to lopinavir/ritonavir (LPV/r) or saquinavir/ritonavir (SQV/r) containing antiretroviral regimens. The retrospective short-term study included 20 patients with LPV/r and 20 patients with SQV/r containing highly active antiretroviral therapy (HAART). At baseline 7 LPV/r patients and 10 SQV/r patients had CD4+T cell counts above 410 cells/μl. After 6 months CD4+T cells had doubled in 5 LPV/r and 2 SQV/r patients. In LPV/r patients the mean serum concentration of lopinavir (LPV) was 2.6 ppm and 67% of all LPV/r samples had 50 or fewer viral copies/ml. In SQV/r patients the mean serum concentration of saquinavir (SQV) was 2.1 ppm. 79% of all SQV/r samples had 50 or fewer viruses/ml. Pharmacoenhanced regimens efficiently suppress human immunodeficiency virus type 1 (HIV-1) and the risk of developing resistance mutations is therefore reduced. The implementation of drug monitoring is an additional tool to determine optimal treatment conditions.
Collapse
Affiliation(s)
- B Falkensammer
- Department of Hygiene, Microbiology and Social Medicine and Ludwig-Bolzmann-Institute for AIDS Research, Innsbruck Medical University, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Patel AK, Patel KK, Naik E, Jingyi Duan, Ranjan R, Patel JK, Salihu HM. Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India. ACTA ACUST UNITED AC 2011; 10:111-8. [DOI: 10.1177/1545109710385121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Atul K. Patel
- Infectious Diseases Clinic, “VEDANTA” Institute of Medical Sciences, Navarangpura, Ahmedabad, India,
| | - Ketan K. Patel
- Infectious Diseases Clinic, “VEDANTA” Institute of Medical Sciences, Navarangpura, Ahmedabad, India
| | | | | | - Rajiv Ranjan
- Infectious Diseases Clinic, “VEDANTA” Institute of Medical Sciences, Navarangpura, Ahmedabad, India
| | - Jagdish K. Patel
- Adit Molecular Diagnostic Laboratory, “VEDANTA” Institute of Medical Sciences, Navarangpura, Ahmedabad, India
| | | |
Collapse
|
3
|
Petrarca C, Frydas S, Donelan J, Boucher W, Papadopoulou N, Cao J, Castellani ML, Conti P, Toniato E, Robuffo I, Vecchiet J, Iezzi T, Madhappan B, Kempuraj D. Interleukin 27 (IL-27): A novel pleiotropic cytokine involved in T cell differentiation and T cell response modulation. Int J Immunopathol Pharmacol 2005; 18:191-4. [PMID: 15888242 DOI: 10.1177/039463200501800201] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|